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EncephalopathyMitochondria are essential organelles within the cell where most of the energy production occurs by the oxida-
tive phosphorylation system (OXPHOS). Critical components of the OXPHOS are encoded by the mitochondrial
DNA (mtDNA) and therefore,mutations involving this genome can be deleterious to the cell. Post-mitotic tissues,
such asmuscle and brain, are most sensitive to mtDNA changes, due to their high energy requirements and non-
proliferative status. It has been proposed that mtDNA biological features and location make it vulnerable to mu-
tations, which accumulate over time. However, although the role of mtDNA damage has been conclusively con-
nected to neuronal impairment in mitochondrial diseases, its role in age-related neurodegenerative diseases
remains speculative. Here we review the pathophysiology of mtDNA mutations leading to neurodegeneration
anddiscuss the insights obtained by studyingmousemodels ofmtDNAdysfunction. This article is part of a Special
Issue entitled: Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases.
© 2013 Published by Elsevier B.V.1. Introduction
1.1. The mtDNA
1.1.1. Structure
Mitochondrial DNA (mtDNA) was discovered in 1963 [1] and the
human mtDNA fully sequenced in 1981 [2]. The human mitochondrial
genome is a circular, double-stranded, supercoiled molecule composed
of 16569 bp and encoding for 37 genes.
Because of their nucleotide compositions, the DNA strands were
named “H-strand” and “L-strand”, as the heavy strand is rich in guanines,
and light strand is rich in cytosines. The H-strand encodes for 28 genes,
whereas the L-strands encodes for the remaining 9 (Fig. 1).
mtDNA does not contain introns and the majority of the genome is
composed by coding regions, with only a small non-coding portion
(1.1 kb), called the displacement loop (D-loop). The D-loop is essential
for the mtDNA replication and transcription since it contains the origin
of H-strand replication (OH) and the promoter regions of the two strands
(HSP and LSP). The two polycistronic RNAs transcribed from the two
strands are processed to obtain 22 tRNAs molecules, 2 mitochondrial
rRNA and translated into 13 proteins [3].olded Proteins, Mitochondrial
ity of Miami, 1420 NW 9th ave,
s).
vier B.V.All the proteins encoded by the mtDNA are components of the four
OXPHOS multi-subunit complexes. Complex II is the only exception,
as all its components are encoded by the nDNA. The proteins involved
in mtDNA transcription, translation and replication as well as the other
OXPHOS components are all encoded by the nDNA, so that mutations in
these nuclear genes can also affect the stability of the mtDNA (Table 1).
The replication of mtDNA is independent from the cell cycle and, to
date, only few enzymes are known to participate in the process, among
them, POLG (mitochondrial DNA polymerase γ, that has also a 3′–5′
exonuclease/proofreading activity), and Twinkle (a DNA helicase) are
particularly important, as mutations in these genes have been found
in different mitochondrial diseases [4].1.1.2. Mutations
The mtDNA is particularly prone to damage with a mutation rate 10
times higher than that of nDNA [5]. The reasons for this high susceptibility
are several. Unlike nDNA, mtDNA is organized in nucleoids but it is not
protected by histones and its proximity to the mitochondrial respiratory
chain (in particular Complex I and III) makes it also close to a source of
radical oxygen species that are well-known genotoxic agents. Moreover,
it replicates more often than the nDNA and the efﬁciency of repair mech-
anisms appear to be less efﬁcient than the one for nDNA [6]. POLG has an
3′–5′ exonuclease/proofreading activity and TFAM (mitochondrial
transcription factor A) seems to also act as a chaperone protecting it
from oxidative damage [6].
The ﬁrst pathogenic mtDNA mutations were identiﬁed by Holt
at al. and Wallace et al. in 1988 [7,8] and were considered to be
very rare in the total populations. In the last decades an increasing
Fig. 1. Schematic representation of humanmitochondrial DNA. Color codes represent: Grey, the twomitochondrial rRNAs; Yellow, the D-loop containing theH-strand origin of replication
(OH); Light blue, subunits of the Complex I of the mitochondrial electron transport chain; Orange, subunits of cytochrome c oxidase (Complex IV); Violet, subunits of the ATP synthase
(Complex V); Green, the cytochrome b gene, which is part of the Complex III. The black arrows represent the mitochondrial tRNA genes. The red squares indicate the location of the
most common mutations discussed in this review. NSHL: non-syndromic hearing loss; MELAS: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes; MIDD:
Maternally Inherited Diabetes and Deafness; LHON: Leber Hereditary Optic Neuropathy; MERRF: Myoclonic Epilepsy and Ragged RedMuscle Fibers; NARP: Neurogenic muscle weakness,
Ataxia, and Retinitis Pigmentosa.
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much higher than previously expected (N1/200 live births), although in
most cases they are present in low, non-pathogenic levels [9].
1.1.3. Homoplasmy and heteroplasmy
Multiple copies of mtDNA (approximately 100 to 10,000 copies)
exist in most cells, and these levels can vary depending on energy
demands [10]. If all the mtDNAmolecules present in a cell are iden-
tical (all wild-type or all carrying a mutation), this condition is
known as homoplasmic. When mtDNA with different sequences
(pathogenic or not) are present in a single cell, the condition is
known as heteroplasmy. The latter is common for pathogenic mu-
tations, as only a portion of the cellular mtDNA content is affected
(Table 2).
Heteroplasmy is a major factor that determines the clinical severity
of mitochondrial diseases as mitochondrial function only begins to be
affected when there is a relative high number of mutated mtDNA
compared to wt, usually N70–80% [11,12]. This phenomenon is known
as “threshold effect” [13] and it can vary depending on the mutation,
the cell type, the tissue or even depending on affected individual.
Heteroplasmy can be dynamic, changing during the lifetime in both
mitotic and postmitotic tissues, due to the cell-cycle-independent
mtDNA replication [14,15].1.1.4. Maternal inheritance
The lack of paternal inheritance of mtDNA in vetebrates is believed
to be due to both a dilution effect, since sperm contains 1000 times
less mitochondria compared to the unfertilized egg, and to the so-
called mtDNA bottleneck. During the phases of primordial germ cells,
mtDNA content falls to very low levels, preventing the transmission of
pathogenic mtDNA mutations.
Maternal inheritance is a very important factor to take in consid-
eration during the diagnosis of a mitochondrial disease since the
transmission occurs only through the mother.1.1.5. Pathogenic mtDNA changes
MtDNA defects can be maternally inherited or sporadic. Point muta-
tions are, in general, maternally inherited and heteroplasmic, with an
estimated incidence of 1:5000 [16]. They can affect mtDNA-encoded
proteins, tRNA or rRNA, and eventually ATP production.
MtDNA rearrangements, like large-scale deletions, remove large
portions of the mtDNA, with consequent ablation of various genes,
depending on the site and size of the deletion. They are consistently
heteroplasmic and sporadic and even though the exact mechanism of
formation is still controversial, it is believed that they can derive from
errors in replication or inefﬁciency of the mtDNA repair system [17,18].
Their levels may increase during life as deleted mtDNA molecules were
reported to have a replicative advantage [19,20]. They manifest a
pathogenic effect at a lower threshold (approximately 60%) compared
to most point mutations [13].
2. Neuronal susceptibility: post-mitotic tissues sensitivity to
mitochondrial dysfunctions
Mitochondrial diseases caused by mtDNA mutations are in general
multi-symptomatic diseases with dysfunctions affecting different sys-
tems and tissues (loss of muscle coordination, muscle weakness, visual
problems, hearing problems, learning disabilities, heart disease, liver
disease, kidney disease, gastrointestinal disorders, respiratory disorders,
neurological problems, diabetes, autonomic dysfunction and dementia).
The most affected tissues are the post-mitotic ones, such as myocytes
and neurons. The reasons for this particular susceptibility lie in the
non-proliferative nature of these cells, making it difﬁcult to eliminate
cells with high levels of damaged or mutated mtDNA.
The cell-cycle-independent replication of mtDNA and the co-
existence of wt and mutated molecules of mtDNA are the cause of the
different load of heteroplasmy in different cell types and tissues. In mi-
totic tissues not all the cells will contain the same amount of damaged
mtDNA so that the daughter cells with high levels of mtDNA mutation
could be in energetic disadvantage and replaced during the lifespan of
an individual [14]. On the other hand, in post-mitotic cells, like
Table 1
List of mitochondrial tRNAs gene mutations associated with phenotypes affecting predominantly the CNS (Source: MITOMAP).
Mutation Gene Syndromes Symptoms
Deafness/neurosensory hearing loss
A7445G tRNASer(UCN) Deafness/Neurosensory Hearing Loss Neurosensory Hearing Loss
T7511C tRNASer(UCN) Deafness/Neurosensory Hearing Loss Neurosensory Hearing Loss
T7510C tRNA Ser (UCN) Deafness; Neurosensory Hearing Loss Neurosensory Hearing Loss
T7511C tRNA Ser(UCN) Deafness; Neurosensory Hearing Loss Neurosensory Hearing Loss
7472insC tRNA Ser(UCN) Deafness; cerebellar dysfunction Neurosensory Hearing Loss and Cerebellar Dysfunction
T14709C tRNA Glu Deafness; Ataxia and MR Neurosensory Hearing Loss, Mental Retardation, Cerebellar
Dysfunction
Encephalomyopathy
G583A tRNA Phe Encephalomyopathy, MELAS MELAS/mitochondrial myopathy & exercise intolerance
G1606A tRNA Val Encephalomyopathy, ataxia, myoclonus, and deafness Ataxia, Myoclonus and Deafness
A3243G tRNALeu(UUR) Encephalomyopathy, MELAS MELAS/Leigh Syndrome
C3256T tRNALeu(UUR) Encephalomyopathy, MELAS MELAS
T3271C tRNALeu(UUR) Encephalomyopathy, MELAS MELAS
T3291C tRNALeu(UUR) Encephalomyopathy, MELAS MELAS/Myopathy/Deafness, Cognitive Impairment
G4332A tRNA Gln Encephalomyopathy, MELAS MELAS/encephalopamyopathy
A5537insT tRNA Trp Encephalomyopathy, Leigh syndrome Maternally Inherited Leigh Syndrome
C7472insC tRNA Ser (UCN) Encephalomyopathy Progressive Encephalomyopathy/Ataxia, Myoclonus and
Deafness/Motor neuron disease-like
A8344G tRNA Lys Encephalomyopathy, MERRF MERRF
T8356C tRNA Lys Encephalomyopathy, MERRF MERRF
G8363A tRNA Lys Encephalomyopathy, MERRF MERRF/Maternally Inherited Cardiomyopathy/
deafness/Autism/Leigh Syndrome/Ataxia/Lipomas
T10010C tRNA Gly Encephalomyopathy Progressive Encephalomyopathy
G12147A tRNA His Encephalomyopathy, MERRF MERRF-MELAS/cerebral edema
C1624T tRNA Val Encephalomyopathy, Leigh Syndrome Leigh Syndrome
G1644T tRNA Val Encephalomyopathy, Leigh Syndrome Adult Leigh Syndrome
A5537insT tRNA Trp Encephalomyopathy Leigh Syndrome Maternally Inherited Leigh Syndrome
G611A tRNA Phe Encephalomyopathy MERRF MERRF
G8361A tRNA Lys Encephalomyopathy MERRF MERRF
G8363A tRNA Lys Encephalomyopathy MERRF MERRF/Maternally Inherited Cardiomyopathy, deafness/Autism
G3255A tRNALeu (UUR) Encephalomyopathy MERRF MERRF/KSS overlap
A7543G tRNA Asp Encephalomyopathy Myoclonus and Psychomotor Regression Myoclonic Epilepsy and Psychomotor Regression
G1606A tRNA Val Encephalomyopathy Ataxia, Myoclonus and Deafness Ataxia, Myoclonus and Deafness
G3244A tRNALeu (UUR) Encephalomyopathy MELAS MELAS
A3252G tRNALeu (UUR) Encephalomyopathy MELAS MELAS
T3258C tRNALeu (UUR) Encephalomyopathy MELAS MELAS/Myopathy
T3291C tRNALeu (UUR) Encephalomyopathy MELAS MELAS
G1642A tRNA Val Encephalomyopathy MELAS MELAS
G583A tRNA Phe Encephalomyopathy MELAS MELAS
C3093G 16S rRNA Encephalomyopathy MELAS MELAS
T3271delT tRNALeu(UUR) Encephalomyopathy Progressive Encephalomyopathy
C3287A tRNALeu (UUR) Encephalomyopathy Encephalomyopathy
T4290C tRNA Ile Encephalomyopathy Progressive Encephalomyopathy
C4320T tRNA Ile Encephalomyopathy Encephalocardiomyopathy
G5540A tRNA Trp Encephalomyopathy Encephalomyopathy
T5693C tRNA Asn Encephalomyopathy Encephalomyopathy
T5814C tRNA Cys Encephalomyopathy Encephalopathy
A5816G tRNA Cys Encephalomyopathy Progressive Dystonia
T7512C tRNA Ser (UCN) Encephalomyopathy Progressive Encephalomyopathy, MERRF/MELAS
G8328A tRNA Lys Encephalomyopathy Encephalopathy
A8332G tRNA Lys Encephalomyopathy Dystonia and stroke-like episodes
T10010C tRNA Gly Encephalomyopathy Progressive Encephalomyopathy
G15915A tRNA Thr Encephalomyopathy Encephalomyopathy
C2835T rRNA 16S Encephalomyopathy Rett Syndrome Rett Syndrome
A10044G tRNA Gly Encephalomyopathy Gastrointestinal Reﬂux/Sudden Infant Death Syndrome
G8313A tRNA Lys Mitochondrial Myopathy Mitochondrial Neurogastrointestinal
Encephalomyopathy
Neurogastrointestinal encephalomyopathy
Encephalopathy
A10438G tRNA Arg Encephalopathy Progressive Encephalopathy
C14680A tRNA Glu Encephalopathy Mitochondrial Encephalopathy
A14696G tRNA Glu Encephalopathy Progressive Encephalopathy
G14724A tRNA Glu Encephalopathy Mitochondrial Leukoencephalopathy
G14740A tRNA Glu Encephalopathy Encephalopathy + Retinopathy
G15967A tRNA Pro Encephalopathy MERRF-like disease
C15975T tRNA Pro Encephalopathy Ataxia+retinopathy+deafness
G4284A tRNA Ile Multisystem Disease Varied familial presentation
G12207A tRNA Ser (AGY) Mitochondrial Myopathy/Encephalopathy Myopathy/Encephalopathy
A4269G tRNA Ile Fatal Infantile Cardiomyopathy Plus (MELAS) Fatal Infantile Cardiomyopathy Plus
A4317G tRNA Ile Fatal Infantile Cardiomyopathy Plus (MELAS) Fatal Infantile Cardiomyopathy Plus
Other
T1659C tRNA Val Movement Disorder Movement Disorder
G3196A rRNA 16S Alzheimer & Parkinson Disease Alzheimer & Parkinson Disease
T4336C tRNA Gln Alzheimer & Parkinson Disease; Deafness & Migraine Alzheimer & Parkinson Disease/Hearing loss and migraine
G5549A tRNA Trp Dementia and Chorea Dementia and Chorea
T5728C tRNA Asn Multi-organ Failure Multi-organ failure
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Table 2
List of protein-encoding mtDNA mutations associated with phenotypes affecting predominantly the CNS (Source: MITOMAP).
Mutation Gene Syndromes Symptoms
Dystonia/Leigh syndrome
A3796G MTND1 Adult-onset dystonia Dystonia
T8993C MTATP6 Leigh Syndrome/Neuropathy Ataxia and Retinitis Pigmentosa (LS/NARP) Leigh syndrome/Neuropathy Ataxia and Retinitis Pigmentosa
T8993G MTATP6 NARP Neuropathy Ataxia and Retinitis Pigmentosa
T9176G MTATP6 LS Leigh syndrome
T9176C MTATP6 LS/familial bilateral striatal necrosis Leigh syndrome
T9185C MTATP6 LS/Ataxia/NARP-like disease Leigh syndrome/Neuropathy Ataxia and Retinitis Pigmentosa
T9191C MTATP6 LS Leigh Syndrome
C9537insC MTCO3 LS-like Leigh Syndrome
T10158C MTND3 LS Leigh syndrome
T10191C MTND3 LS/LS-like Disease/Epilepsy, Strokes, Optic atrophy, and Cognitive decline Leigh syndrome
G10197A MTND3 LS/Dystonia/Stroke Leigh syndrome
C11777A MTND4 LS Leigh syndrome
T12706C MTND5 LS Leigh syndrome
G14459A MTND6 Leber hereditary optic neuropathy and dystonia/LS Dystonia/Leigh syndrome
T14487C MTND6 LS/dystonia/ataxia Dystonia/Leigh syndrome
Encephalomyopathy
T3308C MTND1 MELAS Encephalomyopathy, MELAS
G3376A MTND1 MELAS/LHON Encephalomyopathy, MELAS
G3697A MTND1 MELAS/LS Encephalomyopathy, MELAS
G3946A MTND1 MELAS Encephalomyopathy, MELAS
T3949C MTND1 MELAS Encephalomyopathy, MELAS
A11084G MTND4 MELAS Encephalomyopathy, MELAS
A12770G MTND5 MELAS Encephalomyopathy, MELAS
A13045C MTND5 MELAS/LHON/LS overlap syndrome Encephalomyopathy, MELAS, optic neuropathy
G13513A MTND5 MELAS/LS Encephalomyopathy, MELAS
A13514G MTND5 MELAS Encephalomyopathy, MELAS
A13084T MTND5 MELAS/LS Encephalomyopathy, MELAS
G14453A MTND6 MELAS Encephalomyopathy, MELAS
14787del4 MTCYB MELAS/Parkinson's-like Encephalomyopathy, MELAS, Parkinsonism
C6489A MTCO1 Therapy-resistant epilepsy Encephalomyopathy, Epilepsy
G6930A MTCO1 Multisystem disorder Encephalomyopathy, Multisystem Disorder
6015del5 MTCOI Myopathy and cortical lesions Encephalomyopathy, Multisystem Disorder
T7587C MTCO2 Encephalomyopathy Encephalomyopathy
G7896A MTCO2 Multisystem disorder Encephalomyopathy, Multisystem Disorder
8042del2 MTCO2 Lactic acidosis Encephalomyopathy, Lactic Acidosis
G9952A MTCO3 Encephalomyopathy Encephalomyopathy
T9957C MTCO3 MELAS/progressive encephalopathy/non‐arteritic ischaemic optic neuropathy Encephalomyopathy, MELAS
9205del2 MTATP6 Lactic acidosis/seizures Encephalomyopathy, Lactic Acidosis
A15579G MTCYB Multisystem disorder Encephalomyopathy, Multisystem Disorder
T14849C MTCYB Septo-optic dysplasia Encephalomyopathy, Septo-Optic Dysplasia
Deafness/sensorineural hearing loss
G11778A MTND4 LHON Optic neuropathy, Sensory Neural Hearing Loss
G3460A MTND1 LHON Optic neuropathy, Sensory Neural Hearing Loss
T14484C MTND6 LHON Optic neuropathy, Sensory Neural Hearing Loss
G7444A MTCO1 Sensory neural hearing loss/LHON ,Sensory Neural Hearing Loss, optic neuropathy
A8108G MTCO2 Sensory neural hearing loss Sensory Neural Hearing Loss
C14340T MTND6 Sensory neural hearing loss Sensory Neural Hearing Loss
Alzheimer and Parkinson-like presentations
A3397G MTND1 ADPD Alzheimer & Parkinson disease
G5460A MTND2 AD Alzheimer’s disease
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mitotic segregation. The replication of mtDNA in post-mitotic tissues
causes a clonal expansion and consequent accumulation of somatic
pathogenic mtDNA mutations (Table 3).
Myocytes and neurons are also cells with a high-energy demand.
This characteristic makes them more vulnerable to the ATP depletion
that can derive from the pathogenic mutations in themtDNA that affect
proteins involved in the respiratory chain [21].
3. Neurodegeneration in mitochondrial diseases
3.1. Mitochondrial encephalopathies caused by MtDNA deletions
Patients with mtDNA large deletions commonly show one of
three classic phenotypes: Pearson Syndrome, chronic progressive
external ophthalmoplegia (CPEO) and Kearns–Sayre syndrome
(KSS). Patients with Pearson Syndrome show a multi-symptomatic
disease from birth with a 50% surviving rate after 4 years of age.
The main symptoms are sideroblastic anemia and exocrine pancreasdysfunction. Those who survive infancy are expected to develop KSS
[22–24]. CPEO is characterized by ptosis and ophthalmoplegia with
some patients showing also oropharyngeal and proximal muscle
weakness. Patients with CPEO can have brain, inner ear, and retinal
disease in later stages of the disease, depending on the age of onset
and on the level of heteroplasmy [25]. CPEO is commonly seen as a
milder form of the disease, and clinical presentations can involve
other muscles or symptoms and are sometimes referred to as CPEO Plus
[26].
Although it is a multisytem disorder, CNS involvement is evident in
KSS. The syndrome is deﬁned by onset prior to 20 years of age, progres-
sive external ophthalmoplegia (PEO), and a pigmentary retinopathy
(usually rod-cone dystrophy). Moreover, patients may also show cardiac
conduction block (usually the cause of death in young adulthood),
elevated cerebrospinal ﬂuid protein level, or cerebellar ataxia [26].
Other neurologic problems may include proximal myopathy, exercise
intolerance, ptosis, oropharyngeal and esophageal dysfunction, sensori-
neural hearing loss, dementia, and choroid plexus dysfunction resulting
in cerebral folate deﬁciency [27].
Table 3
List of nuclear DNA-encoded genes involved in mtDNA integrity associated with phenotypes affecting predominantly the CNS.
Name Function Inheritance Clinical phenotype
POLG1 Polymerase gamma, mtDNA replication AD-AR Alpers syndrome, AD-PEO and AR-PEO, male infertility, SANDO*
syndrome, SCAE*
POLG2 Catalytic subunit of DNA polymerase gamma, mtDNA replication AD AD-PEO
ANT1 Adenine nucleotide translocator isoform 1, dNTPs pool maintenance AD AD-PEO, multiple mtDNA deletions
MPV17 Unknown, involved in the metabolism of reactive oxygen species and
in the regulation of mtDNA copy number
AR Hepatocerebral MDDS
Twinkle (C10orf2) Twinkle helicase, mtDNA replication AD AD-PEO, SANDO syndrome
TYMP Thymidine phosphorylase, dNTPs pool maintenance AR MNGIE, mtDNA depletion
DGUOK Deoxyguanosine kinase Mitochondrial, dNTPs pool maintenance AR Hepatocerebral mtDNA depletion syndrome
RRM2B Ribonucleotide reductase, dNTPs pool maintenance AR Encephalomyopathic Renal tubulopathy MNGIE, AD-PEO
SUCLA2 Succinate-CoA ligase, ADP-forming, beta subunit AR Encephalomyopathy with methylmalonic aciduria
SUCLG1 Succinate-CoA ligase, alpha subunit AR Encephalomyopathy with methylmalonic aciduria
MGME1 (C20orf72) mitochondrial genome maintenance exonuclease 1 AR Mitochondrial DNA depletion syndrome 11
DNA2 helicase/nuclease, mtDNA replication, long-patch base-excision repair
pathway
AD PEO
TK2 Thymidine kinase mitochondrial, dNTPs pool maintenance AR Myopathic mtDNA depletion
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Almost 600 pathogenic point mutations have been identiﬁed in the
last 25 years, involving most of the mtDNA molecule (according to
MITOMAP, 299 point mutation involving tRNA–rRNA and control
regions and 274 involving OXPHOS proteins).
The most commonmitochondrial encephalopathies caused by point
mutations can be classiﬁed in clinical categories: LHON (Leber Heredi-
tary Optic Neuropathy), Leigh Syndrome,MELAS (Mitochondrial myop-
athy, encephalomyopathy, lactic acidosis, stroke-like symptoms), MIDD
(maternally inherited diabetes and deafness), MERRF (Myoclonic Epi-
lepsy with Ragged Red Fibers), non-syndromic hearing loss and NARP
(Neuropathy, ataxia, retinitis pigmentosa).
Approximately 95% of LHON cases show a mutation in one of three
mtDNA genes: G11778A, G3460A or T14484C, respectively encoding for
ND4, ND1 and ND6, all subunits of Complex I of the electron transport
chain (Fig. 1). The main characteristic of the disease is a painless,
bilateral, subacute or acute visual failure, prevalently in young male
adults, caused by the atrophy of the optic nerve [28]. Neurodegeneration
is limited to the retinal ganglion cell (RGC) layerwith cell body and axonal
degeneration, demyelination and atrophy observed from the optic nerves
to the lateral geniculate bodies [29]. One possible explanation for the in-
volvement of the optic nerve alone is the disruption of glutamate trans-
port out of the inner retina with consequent excitotoxic damage [30].
There is a correlation between genotype and the severity of the disease:
patients with the G11778A mutation seem to have the most severe
phenotype, with the least favorable visual outcome, while the
T14484C mutation is associated with the mildest pathogenicity [31].
Leigh Syndrome can be caused by different mutations, both in
mtDNA and in nDNA genes. Mutations can occur in genes encoding for
tRNAs as well as in genes encoding for complexes I, IV, or V of the
OXPHOS [32–37] and are commonly present in heteroplasmy. The
heterogenic symptoms include motor and intellectual developmental
delay, bilateral brainstem disease, basal ganglia disease, elevated blood
or CSF lactate levels, hypotonia, spasticity, chorea and other movement
disorders, cerebellar ataxia, peripheral neuropathy, and respiratory
failure secondary to brainstem dysfunction [35]. The condition may
also affect the liver, heart (including hypertrophic cardiomyopathy),
kidneys, and pancreas [38].
About 80% of MELAS cases are caused by a very common A3243G
mutation in the mitochondrial tRNALeu(UUR) gene, whereas 10% of
cases carry the T3271C mutation in the same tRNALeu(UUR) (Fig. 1),
although other mtDNA point mutations have been also associated
with this phenotype (MITOMAP). As the vast majority of the mito-
chondrial diseases, this is a multisystemic disorder with symptoms
varying depending on the heteroplasmy status and on the age of
onset. Other than mitochondrial myopathy, encephalomyopathy,lactic acidosis and stroke-like symptoms, patients can also show
deafness, diabetes, migraines, gut immobility and seizures [39].
Multiple strokes affect the patients, mainly in the cerebral cortex or
in the subcortical white matter, causing multifocal necrosis with lesions
that do not respect vascular territories and are often accompanied by
profound neuronal cell loss, neuronal eosinophilia, astrogliosis and
spongiformdegeneration [40]. There is also a loss of Purkinje cells causing
cerebellar degeneration and a particularly prominent calciﬁcation in
the basal ganglia. Depending on the portions of the brain affected by the
ischemic lesions, symptoms may vary from focal status epilepticus and
epilepsia partialis continua to just occipital migraines and a visual aura.
A3243G is also the most frequent mutation associated with MIDD
(maternally inherited diabetes and deafness) [41] in fact, patients diag-
nosed with this disease may also have typical symptoms of MELAS
including myopathy, cardiomyopathy, neuropsychiatric symptoms,
and renal disease and patients belonging to the same family can have
MELAS or MIDD. The level of heteroplasmy can explain in part the
different clinical outcome [42].
The neurodegeneration that typically causes the sensorineural deaf-
ness involves the auditory nerve or the brain, with defect in oxidative
phosphorylation in the beta cells that sense glucose and diminished
ATP production by strial marginal cells of the inner ear [43].
In 90% of the cases of MERRF, themutation responsible is an A8344G
transition, in the tRNALys, [44] (Fig. 1). Themyoclonic epilepsy is themain
symptom associated with this disease together with the presence of
clumps of diseased mitochondria accumulation in the sub-sarcolemmal
region of the muscle ﬁber called “Ragged Red Fibers.” Other symptoms
like ataxia, neuropathy, and cardiac abnormalities can be present. Curi-
ously, many patients with the A8344Gmutation also showmultiple lipo-
mas in the back region [45]. Themain neuropathological signs involve the
olivocerebellar pathway,with severe neuron loss from the inferior olivary
nucleus, Purkinje cells, and dentate nucleus. Neurodegeneration is
present also in the gracile and cuneate nuclei, moreover there are
signs of demyelination of the spinal cord [46]. In the surviving neurons
there are evidences of respiratory chain deﬁciency and presence of en-
larged mitochondria containing inclusions [47]. No clear correlation has
been identiﬁed between genotype or heteroplasmy and clinical pheno-
type, nor it is clear why typical MERRF is associated with mutations in
tRNALys [48].
Non-syndromic hearing loss, that means severe and profound deaf-
ness not associated to other neurologic or systemic diseases, can be
caused by mutations in mitochondrial tRNAs like A3243G, A7443/4/5G,
and in rRNAs like 961delT, and A1555G [49] (Fig. 1).
NARP is associated mainly with the mutation T8993G (or T8993C)
in the mtDNA encoding for the MTATP6 gene, even though a family
with a G8989C mutation has also been described [50] (Fig. 1). This
disease is characterized by sensory or sensorimotor axonal neuropathy,
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and retinitis pigmentosa. Other non-typical neurological symptoms, in-
cluding seizures, learning problems, hearing loss, progressive external
ophthalmoplegia, and anxiety can be present.
3.3. Mitochondrial diseases caused by mutations in nDNA genes affecting
mtDNA stability
MtDNA changes can be a consequence of mutations in nDNA-
encoded genes involved in the maintenance of mtDNA integrity and
mtDNA copy number. The most common mutations affect POLG, the
gene encoding for the catalytic subunit of the mitochondrial DNA
polymerase gamma, and PEO1 which encodes for the DNA helicase
Twinkle [51,52], both genes involved in mtDNA replication. Mutations
in these genes provoke an accumulation of mtDNA point mutations
and deletions eventually leading to a different clinical manifestation.
Over 200mutations in POLG associated withmitochondrial diseases
have been identiﬁed, causing a plethora of heterogeneous disorders
involving different tissues, time of onset and severity. At least ﬁve
major phenotypes can be distinguished: Alpers–Huttenlocher syndrome,
childhood myocerebrohepatopathy spectrum, myoclonic epilepsy
myopathy sensory ataxia, the ataxia neuropathy spectrum, and progres-
sive external ophthalmoplegia (PEO) with or without sensory ataxic
neuropathy and dysarthria [53–56]. Patients with mutations in POLG
also show defects in complex I and complex IV in dopaminergic neurons
of the substantia nigra and neuronal cell loss [57,58].
Recessive mutations in Twinkle protein cause severe, early-onset
disorders due also to defects in mtDNA maintenance, such as infantile-
onset spinocerebellar ataxia and a hepatocerebral mtDNA depletion
disorderwith severe epilepsy,migraine, and psychiatric symptoms [55].
Also TYMP, that encodes for thymidine phosphorylase and is essential
in the nucleotide salvage pathway for mtDNA replication, is typically
mutated (multiple deletions and single base changes) in mitochondrial
neurogastrointestinal encephalomyopathy [59,60].
Mutations in OPA1, a protein involved in the mitochondrial fusion
process, cause autosomal dominant optic atrophy with loss of retinal
ganglion cells and progressive optic nerve degeneration with cases of
more severe neuromuscular complications [61,62]. RRM2B encodes a
ribonucleotide reductase and is mutated in cases of autosomal dominant
OPA [63,64]. Mutations in both genes cause mtDNA instability and
multiple deletions.
Changes in mtDNA copy number are also associated with clinical
syndromes. The MDS (mtDNA depletion syndromes) are autosomal
recessive disorders caused by mtDNA depletion in clinically affected
tissues [65]. Most of them derive from a mutation in nDNA genes in-
volved in mtDNA replication machinery (POLG, Twinkle) or in different
mitochondrial functions like nucleotide metabolism (TYMP, TK2, DGUOK
andMPV17) or ﬁssion–fusionmachinery (Mfn2) [66–70]. Phenotypically
they are very heterogeneous with myopathic, encephalomyopathic,
hepatocerebral or neurogastrointestinal manifestations, with a common
neurological involvement [69,71].
4. mtDNA changes in age-related neurodegenerative diseases
MtDNA changes have been hypothesized to have a role also in age-
related neurodegenerative diseases like Parkinson's (PD), Alzheimer's
(AD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
PD is the second most common progressive neurodegenerative disorder,
mainly characterized bymotor (resting tremor, postural instability, rigid-
ity and bradykinesia) and non-motor symptoms (fatigue, depression,
anxiety, sleep disturbances, autonomic disturbances, decreased motiva-
tion, apathy and a decline in cognition, dementia). The cause of the
motor symptoms is a depletion of dopamine in the striatum, derived
from a speciﬁc degeneration of dopaminergic neurons located in the
midbrain and forming the substantia nigra (SN). The etiology of this disor-
der is still unknown, but a role of mitochondrial dysfunction, and inparticular of Complexes I and IV of the electron transport chain, has
been proposed in the last decades and extensively reviewed [72–75]. Dif-
ferent hypotheses have been proposed to explain the high suscepti-
bility of SN to mitochondrial stress and to mtDNA damage, and the
anatomical characteristics of these neurons, that have particularly
long unmyelinated axons, seem to be the most accredited [76,77].
More speciﬁcally, different groups have also analyzed mtDNA changes
in patients' post-mortem brain: high levels of mutations and deletions
are found within the neurons of the SN both in patients with PD and
during normal aging [78,79].
If mtDNA changes are sufﬁcient to confer PD symptoms is still
controversial, studies on animal models [80–82] and the fact that
patients with POLG mutations also show Parkinsonism similar to cases
of juvenile PD [57,83] suggest that they play a role in the pathogenesis.
Moreover, it has also been suggested that different mtDNA haplotypes
can confer higher or lower risk factors to develop PD, because different
polymorphisms can show subtle differences of the respiratory chain
activity and ROS production. In particular, the super-haplogroup JT
seems to confer a reduced risk of PD while the super-haplogroup HV
seems to be associated with an increased risk [84].
AD is the most common late-onset progressive neurodegenerative
disease, clinically characterized by memory loss, impairment of cogni-
tive functions and changes in behavior and personality. The neurode-
generation that occurs in these patients affect mostly the cortex and
the hippocampus. Here there is an accumulation of senile plaques,
composed mainly by beta-amyloid peptide, and intraneuronal tau
deposition as neuroﬁbrillary tangles. The most studied pathogenetic
model for this disease is the “beta-amyloid cascade”, where an unbal-
ance in the cleavage sequence of APP (amyloid precursor protein)
leads to an accumulation of toxic Aβ fragment, cytotoxic plaques, and
consequent neurodegeneration.
Mitochondrial dysfunctions, in particular cytochrome c oxidase
defects, have also been implicated in the development and progression
of AD [85,86]. Aβ fragments negatively affect mitochondrial function,
suggesting that mitochondrial dysfunction is a consequence of the Aβ
toxicity, moreover studies in AD mouse models show also that Aβ
oligomerization impairs mitochondrial function [87–90]. Moreover,
the γ-secretase activity and so the APP cleavage, occurs predominantly
in the MAM (mitochondria-associated ERmembranes), a compartment
of the endoplasmic reticulum physically and biochemically connected
to mitochondria. MAM function and ER–mitochondrial connectivity
are increased in AD, so that AD is also proposed to be an ER–mitochon-
drial communication and MAM dysfunction disease [91,92]. This hy-
pothesis, other than the β-amyloid cascade one, would explain also
other biochemical changes occurring in the disease like mitochondrial
dysfunction, elevated levels of cholesterol, altered metabolism of fatty
acids and phospholipids, and aberrant calcium homeostasis [93].
The presence of increasedmutations in mtDNA of AD patients is still
a controversial subject: different laboratories with various groups of
patients and dissimilar techniques have obtained debatable results
[94–98]. It has also been suggested that inherited haplogroups may
inﬂuence AD risk but to date, no clear result has been found [99].
ALS is a motor neuron disease, characterized by rapidly progressive
weakness, muscle atrophy and fasciculation, muscle spasticity, dysar-
thria, dysphagia, dyspnea caused by the degeneration of the upper
and lower motor neurons. Increased mtDNA deletions have been
found in muscle and brain of ALS patients, although the levels are
still relatively low and of unknown consequence [100–102]. Moreover
in some cases of patients with mtDNA mutations, an ALS phenotype
has been diagnosed [103–106]. Also in this case the association of
haplogroup with increased risk factor is still controversial [107].
MS is a chronic inﬂammatory autoimmune disease caused by loss of
myelin and gliosis. The etiology of this disease is largely unknown and
hypothesis on genetic, environmental and infective agents have been
analyzed without a clear response. A mitochondrial role has been
proposed since changes in the expression of TFAM, PGC1α and nuclear
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patients [108,109]. Moreover in patients' post-mortem brains, there is
a reduction of Complex I and Complex III activity [110]. Different
mtDNA mutations have been reported in patients with MS [111] even
though the direct role of mtDNA single mutation or deletion in the
pathogenesis of this disease is also still controversial [112].
5. Mouse models of mtDNA alterations in neurodegenerative
conditions
As described in the previous paragraphs, mtDNA changes have been
implicated in a vast group of diseases and possibly normal aging. In
order to study the mechanisms behind these pathologies, the use of
mouse models is compelling. Unfortunately, engineering and integrating
speciﬁc mtDNAmutations in mice, in particular pathogenic mutations, is
technically challenging, most of all because of the “bottleneck effect”
[113]. The speciﬁc mutation in mice will be diluted in the progeny so
that to date, mouse models with pathological mtDNA mutations are
rare [114] and, if not lethal, kept in homoplasmy [115].
As detailed below, the modeling of mtDNA changes has been
approached in two alternative ways: by engineering nuclear genes or by
direct manipulation of mtDNA [116]. On one side, mouse models with
mtDNA mutations have been created by genetic modiﬁcation of nDNA
encoded genes involved in mtDNA maintenance like POLG, Tfam and
Twinkle, on the other hand speciﬁc deletions have been created in the
mtDNAby the introduction of defectivemitochondria intomouse zygotes
or by the expression of restrictionmitochondria-targeted endonucleases.
5.1. Manipulation of nDNA encoded genes that affect mtDNA
One of the ﬁrst nDNA-encoded genes to be targeted in order to
induce an indirect damage to mtDNA was TFAM. It is a transcriptional
activator that binds mtDNA promoters and activates transcription. It is
also necessary for mtDNA replication since it provides the RNA primers
for initiation and it has an important histone-like role in mtDNA main-
tenance since it binds to mtDNA coating it [117]. Tfam KO mice
completely lack mtDNA and die during embryogenesis. Tissue-speciﬁc
disruption of Tfam shows different clinical evidences, in particular
neurodegeneration is present when Tfam is knocked out in forebrain
neurons (MILON mice) and in dopaminergic cells (MitoPark mouse).
In MILON mice, Tfam was deleted post-natally, showing no sign of
disease until 6–8 months of age, when deteriorating conditions and
death appeared in 2–3 weeks caused by signiﬁcant mtDNA depletion
[118]. In Mito-Park mice, Tfam was deleted in dopaminergic neurons,
causing a Parkinson-like phenotypewith dopamine depletion, neurode-
generation of dopaminergic cells of substantia nigra and motor deﬁcits
[119].
POLG is also essential for mtDNA replication, so that POLG KO mice
are embryonically lethal [120]. In order to induce mtDNA damage in
different tissues, Polg gene has been manipulated to impair its proof-
reading activity. Two different groups created the “mutator mouse” by
knocking-in PolgA gene carrying two different mutations: the D257A
mutation [121] or the AC → CT substitution in positions 1054 and
1055 [122]. These mutations provoked an accumulation of mtDNA
pointmutations in different tissues [123], causing two very similar clin-
ical phenotypes. The mutator mice showed signs typical of premature
aging, with reduced life span, kyphosis, alopecia, weight loss, reduced
fat content, osteoporosis, thymic involution, testicular atrophy, loss of
intestinal crypts, progressive decrease in circulating red blood cells,
hearing loss and sarcopenia. Surprisingly thesemice did not show strik-
ing signs of neurodegeneration [124]. Nonetheless, detailed studies of
brain mtDNA by NextGen sequencing show that brain of mutator mice
accumulate mtDNA species with abnormal D-loop structures. These
control region multimers (CRMs) may reﬂect disrupted replication
events, although their functional consequences are unknown [123].As previously described, Twinkle has a helicase activity essential for
mtDNA replication andmaintenance. The Twinkle A360T mutation and
aa 353–365 duplication are typical of PEO so that Twinkle mice have
been generated knocking in the mutated gene [125] resulting in an
accumulation of multiple large mtDNA deletions mostly in brain and
muscle. These transgenic mice show progressive mitochondrial
myopathy and mitochondrial impairment in cerebellar Purkinje
cells and hippocampal CA2 pyramidal neurons.
Other nDNA-encoded genes have been manipulated to indirectly
affect mtDNA stability. Among them, TYMP/UP KO mice, who lack
thymidine phosphorylase activity, showed partial mtDNA depletion in
brain, late-onset vacuoles in cerebral and cerebellar white matter with-
out demyelination or axonal loss [126].MPV17 KOmice showedmtDNA
depletion in different tissues including brain [127] TK2 KO [128], mu-
tant TK2 knock in mice [129] and RRM2B KO mice [64] also showed
mtDNA depletion. A novel mouse model is also expressing a mutated
version of UNG1 in neurons (that removes thymine, in addition to uracil
from mtDNA), showing signs of neurodegeneration and impaired be-
havior [130].
5.2. Direct damage to mtDNA
The “mito-mice” [131] have been generated by introducing exoge-
nous mitochondria carrying mutated mtDNA into mouse zygotes. Three
mito-mice have been generated so far, aΔmtDNA (carrying a 4696 bp de-
letion), mtDNA-COI (carrying T6589Cmutation inmtDNA gene encoding
cytochrome c oxidase subunit I) and mtDNA-ND6 (with A13997Gmuta-
tion in mtDNA gene encoding NADH dehydrogenase 6) [132–134].
ΔmtDNAmice show various percentage of heteroplasmy in different tis-
sues and clinical defects resembling the ones of mitochondrial diseases
like low body weight, lactic acidosis, systemic ischemia, hearing loss,
renal failures, and male infertility. Mice with more than 60% ΔmtDNA
show mitochondrial respiration defects in brain and a downregulation
of Calmodulin-dependent Protein Kinase II subunit alpha (CamKIIa) lead-
ing to impairment of spatial remote memory. MtDNA-COI and mtDNA-
ND6 are homoplasmic and show typical signs of COXI or Complex I deﬁ-
ciencies [135]. The disadvantage of the use of these mice is the colony
maintenance:ΔmtDNA is inherited by progeny for only about three preg-
nancies, since the amount ofΔmtDNA in eggs decreaseswith the aging of
the females. Moreover it is difﬁcult to obtain a large population of mito-
miceΔwith the same ΔmtDNA load.
Recently, Lin et al. created a novel animal model of LHON by
introducing the homoplasmic mtDNA ND6P25L mutation into the
mouse [136]. Mice with this mutation exhibited reduction in retinal
function, decline in optic nerve ﬁbers, neuronal accumulation of
abnormal mitochondria, axonal swelling, and demyelination.
The mito-PstI mouse expresses a mitochondria-targeted restriction
endonuclease, mito-PstI, in an inducible and tissue-speciﬁc way, de-
pending on the promoter that controls the expression of the transgene
[137]. Mito-PstI cleaves the mtDNA in two different sizes, leading to
the accumulation of multiple deletions and eventual mtDNA depletion.
When expressed in neurons (under the control of CamKIIα promoter),
it causes different phenotype, depending on the level and timing of
expression. On a high expression from birth, the mice show an acute
neurodegeneration with an abnormal ‘limb-clasping behavior’ at 2
months of age.With a high expression starting at P21,mice progressive-
ly become less active and died before 100-day-old with a severe reduc-
tion of COX activity in the forebrain. When mito-PstI is expressed at
lower levels, mice show no differences in lifespan up to 16 months of
age with no obvious phenotypic abnormalities until 6–8 months,
when they displayed abnormal and progressively worse motor behav-
ior. This phenotype is caused by a progressive neurodegeneration
particularly severe in the striatum and cortex due to a decreased COXI
activity [138,139]. Moreover, when expressed selectively in dopaminer-
gic neurons (under the control of DAT promoter),mito-PstI causes a PD-
like phenotype with progressive motor defect and loss of dopaminergic
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mutations in the pathogenesis of this disorder.
Mito-PstI mice have also been crossed with an ADmousemodel that
shows plaque formation in cortex and hippocampus. When mtDNA
double strand breaks are induced in these mice for twomonths starting
at 6months of age, there is anunexpected reduction of amyloid plaques,
probably because of a misbalance in the secretases activity [140]. The
accumulation of plaques has been associated with oxidative stress,
and these data indicate that inducing mtDNA damage does not neces-
sarily increase oxidative damage. When the levels of mtDNA are
reduced, also the steady-state levels of OXPHOS complexes decrease,
which can lead to a decrease in ROS formation [140].6. Conclusions
Mitochondria are essential organelles that provide energy thanks to
the oxidative phosphorylation process. Since different proteins of the
electron transport chain are encoded by the mtDNA, its stability is nec-
essary for the health of the entire cell and tissue. Changes inmtDNA can
derive from direct mutations and deletions (somatic or inherited), or
from mutations in nDNA encoded genes involved in the maintenance,
stability and replication of the mtDNA. When pathogenic mutations
occur, post mitotic tissues are most vulnerable because of their biologi-
cal characteristics, so that muscle and central nervous systems are often
affected in mitochondrial diseases. Different forms of neurodegenera-
tion are common features of mitochondrial diseases. Although low
levels of mtDNA changes have been described in age-related neurode-
generative disorders like Parkinson's or Alzheimer's diseases, their con-
tribution to the diseases process remains poorly understood. Thanks to
the useful tools developed in the last decades such as different tech-
niques to investigate the mtDNA sequence (including NextGen [123])
and the creation of mouse models, we have now a better idea of the
spectra ofmtDNAmutations observed in aged tissues [141] and the con-
sequences andmolecular features of inducingmtDNAdamage in animal
models [118–136]. Our knowledge about the role of mtDNA alterations
leading to neurodegeneration is likely to increase at an accelerated rate
in the next few years.References
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